Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;96(1):79-85.
doi: 10.1016/j.rvsc.2013.11.007. Epub 2013 Nov 25.

Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation

S Gil  1 , R O Leal  2 , D McGahie  3 , N Sepúlveda  4 , A Duarte  2 , M M R E Niza  2 , L Tavares  2
Affiliations

Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation

S Gil et al. Res Vet Sci. 2014 Feb.

Abstract

Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP's variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol.

Keywords: Feline Immunodeficiency Virus (FIV); Immune-modulation; Oral therapy; Recombinant-Feline Interferon Omega (rFeIFN-ω).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Individual clinical scores for each cat of each group, before and after rFeIFN-ω therapy. SC Group refers to cats treated with the licensed sub-cutaneous protocol while the PO Group refers to cats treated with oral protocol.
Fig. 2
Fig. 2
Total Proteins, Gammaglobulins and Albumin serum levels of FIV positive cats treated with two different protocols of rFeIFN-ω (Mean values ± standard error). The SC Group refers to cats treated with the licensed protocol while the PO Group refers to cats treated with oral rFeIFN-ω. Horizontal lines (---) represent, respectively, the upper and lower limits of the normal range for each parameter.
See this image and copyright information in PMC

References

    1. Ackley C.D., Yamamoto J.K., Levy N., Pedersen N.C., Cooper M.D. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. Journal of Virology. 1990;64:5652–5655. - PMC - PubMed
    1. Addie D. Feline coronavirus infections. In: Green C., editor. Infectious Diseases of the Dog and Cat. Elsevier ed. Elsevier; Missouri: 2012. pp. 92–108.
    1. Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Lutz H., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline infectious peritonitis. ABCD guidelines on prevention and management. Journal of Feline Medicine and Surgery. 2009;11:594–604. - PMC - PubMed
    1. Bracklein T., Theise S., Metzler A., Spiess B.M., Richter M. Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells. American Journal of Veterinary Research. 2006;67:1025–1032. - PubMed
    1. Caney, S.H.C., Finerty, S., Tasker, S., Gruffydd-Jones, T.J., 2003. Treatment of asymptomatic chroniically FIV-infected cats with recombinant feline interferon omega. In: Proceedings of the Annual Conference of the American College of Veterinary Internal Medicine, Charlotte, USA.

Publication types

MeSH terms